MUC1和uPA在上皮性卵巢癌中表达的临床意义

Clinical significance of expression of MUC1 and uPA in epithelial ovarian cancer

目的:探讨原发性卵巢上皮癌(EOC)和正常卵巢组织中MUC1和uPA的表达特点及临床意义。方法:采用免疫组化S-P法,以单克隆抗体C595和#394作为免疫组化的一抗分别检测60例上皮性卵巢癌及20例正常卵巢组织中MUC1和uPA的表达。结果:MUC1和uPA在上皮性卵巢癌原发灶的表达阳性率分别是83.3%(50/60)和73.3%(44/60),在正常卵巢组织中的表达阳性率分别是10.0%(2/20)和5.0%(1/20),两组比较差异有显著性(P<0.05)。MUC1和uPA在上皮性卵巢癌原发灶中大多为中——强度表达,并有趋势与较高的临床分期和较低的病理分级有关。结论:MUC1和uPA在上皮性卵巢癌存在特异的过度表达,有可能作为良好的肿瘤标志物,成为卵巢癌靶向治疗的备选分子。

Objective： To observe the patterns of expression and clinical significance of MUC1 and urokinase plasminogen activator （uPA） in primary epithelial ovarian cancers（EOC） and normal ovaries.Methods： The expression of MUC1 and uPA were examined by immunohistochemistry in 60 EOC and 20 normal ovarian tissues using monoclonal antibodies C595 and #394,respectively.Results： The over-expressions rate of MUC1 and uPA were 83.3%（50/60） and 73.3%（44/60） in EOC respectively,while the rate were 10.0%（2/20） and 5.0%（1/20） in normal ovaries,respectively.The expression of MUC1 and uPA in EOC was significantly higher than that in normal ovarian tissues（P〈0.05）.Most of tumors showed moderate to intensity of expression.The over-expression of MUC1 and uPA was significantly associated with higher clinical stage and lower pathological grade.Conclusion： Over-expression of MUC1 and uPA is frequently found in late stage of ovarian carcinomas.Both MUC1 and uPA are tumor-associated biomarkers and could be used as ideal targets for ovarian cancer targeted therapy.